Search for Bristol-Myers Squibb Co and
  1. April 13, 2014

    Drug groups step up race for hepatitis C treatments

    Drugmakers are stepping up the race for multibillion-dollar hepatitis C treatments after trial data showed how the disease...

  2. April 1, 2014

    Bristol-Myers Squibb: side effects

    One of these things is not like the others, as Big Bird sings. Look at the mega-cap pharma and biotech stocks. In the near...

Special Reports

  1. FT Health Combating Aids 2012

    Scientific advances and unprecedented funding run up against political sensitivities a...
  2. US Innovative Lawyers

    US Innovative Lawyers ranks the top law businesses, in-house legal teams and individua...
Search more Special Reports on this topic.

  1. January 27, 2014

    Hepatitis C: Treated – at a price

    Gemma Peppe lived with hepatitis C for two decades before she – and the teenage son she inadvertently infected at birth –...

  2. FT Alphaville

    December 19, 2013

    The (early) Lunch Wrap

    Good morning New York, FT ALPHAVILLE Izzy continues to expand her theory of money entanglement, a look at the relationship...

  3. December 19, 2013

    AstraZeneca in $4bn buyout of diabetes venture partner

    AstraZeneca is to buy out its joint venture with Bristol-Myers Squibb in a deal worth up to $4.3bn, as it seeks to...

  4. November 8, 2013

    Bristol-Myers Squibb could realise $6bn from diabetes franchise

    Bristol-Myers Squibb could generate up to $6bn from the sale of its diabetes franchise, according to an analyst’s projection...

  5. FT Alphaville

    October 24, 2013

    Does this stock need medicating?

    It’s Shire, of course, reacting to a warning of better than expected earnings. The stock was up 8.7 per cent at 2744p at...

  6. September 16, 2013

    S&P 500 breaks back above 1,700

    The S&P 500 broke back above the 1,700 level in intraday trading on Monday as US equities rallied and bond yields fell...

  7. August 25, 2013

    Amgen’s $10.5bn takeover of Onyx approved by both boards

    Amgen said on Sunday night that its takeover of Onyx, the US cancer drug developer, at $125 a share had been approved by...

  8. July 10, 2013

    Roche to end trials of diabetes drug due to side-effect concerns

    Roche is to terminate trials of a key experimental diabetes drug due to concerns about its side-effects, in a new setback...

  9. June 23, 2013

    AstraZeneca seeks to share drug development cost

    AstraZeneca is considering a big strategic alliance with another pharmaceutical company to share the costs and benefits of...

  10. June 10, 2013

    Markets Insight: The Fed has turned markets upside down

    Stellar performance across most asset classes has been the norm until recently. Equity markets are up sizeably and, in some...

  11. June 3, 2013

    Carmakers help fuel US stocks

    Auto companies were in focus on the first trading day of June, as the S&P 500 recovered from morning losses to finish the...

  12. May 28, 2013

    Pharma M&A: defensive deals

    Another day, another healthcare sector deal. AstraZeneca’s purchase of Omthera on Tuesday is small (maximum value: $443m),...

  13. May 22, 2013

    US stocks step back from intraday highs

    An afternoon sell-off knocked US stocks back from intraday record highs as investors weighed the Federal Reserve’s...

  14. April 29, 2013

    US pharma: spot the difference

    The big US drug companies look eerily alike. Pfizer, Merck, Eli Lilly and AbbVie (formerly Abbott) are all expanding...

  15. April 21, 2013

    The Week Ahead: April 22 – April 28

    Diary commentary from FT reporters; data and company announcements, unless otherwise stated, from Thomson Reuters. Company...

  16. beyondbrics

    April 17, 2013

    Big Pharma says Olá to Brazil

    By Pan Kwan Yuk and Thalita Carrico Brazil’s burgeoning middle class might have helped propel the country to the top of the...

  17. March 21, 2013

    AstraZeneca puts its faith in science

    The new chief executive of AstraZeneca unveiled a $2.3bn restructuring plan to cut staff by 10 per cent over the next three...

  18. January 2, 2013

    Investors hail Abbott Laboratories split

    Investors gave an initial vote of confidence to the decision to split Abbott Laboratories into two businesses, lifting the...

  19. December 20, 2012

    Eli Lilly settles bribery charges

    Eli Lilly, the US pharmaceutical company, has agreed to pay $30m to settle charges that it engaged in a scheme to bribe...

  20. November 30, 2012

    Teva restructuring beckons

    Teva, the world’s largest generic drugs company, unveiled 2013 sales and earnings guidance below market expectations,...

  21. November 29, 2012

    Research: Scientists turn attention to prevention and cure

    “Getting to zero” – meaning no new infections or deaths from HIV – is the slogan for World Aids Day. Until recently such a...

  22. November 29, 2012

    Corporate: Sweetening the pill

    Any significant transaction has challenges – which may be related to regulation, competition or price. And while it is up to...

  23. October 15, 2012

    US equities boosted by retail data

    Citigroup shares gained as the US bank beat market expectations for the third quarter, despite reporting an 88 per cent fall...

  24. August 28, 2012

    AstraZeneca – a new big pill

    A newly arriving chief executive has many tasks: strategy, turnround, growth, redecorating the corner office. Pascal Soriot...

  25. July 15, 2012

    Diagnostics creating ‘niche buster’ drugs

    When US regulators this month authorised a genetic test that determines whether or not patients will benefit from a cancer...

  26. July 2, 2012

    Deal boosts AstraZeneca’s interim chief

    The $7bn planned acquisition of Amylin announced this weekend is an indicator of interest in the fast-growing diabetes...

  27. July 1, 2012

    BMS / Amylin

    Bad habits equal big opportunities. As the world’s population gets fatter, diabetes is on the rise. The World Health...

  28. July 1, 2012

    AstraZeneca eyes more deals after Amylin

    AstraZeneca has the cash and appetite for more new acquisitions, the acting head of the Anglo-Swedish pharmaceutical group...

  29. June 30, 2012

    BMS and AstraZeneca to acquire Amylin

    Bristol-Myers Squibb is to take control of Amylin, the US biotech, in a complex $7bn joint deal with AstraZeneca that will...

  30. June 26, 2012

    FDA accuses Amylin of withholding info

    A top US regulator has accused Amylin, the biotech company, of withholding important information on cardiac side effects of...

  31. June 5, 2012

    BMS / AstraZeneca: good twin, bad twin

    They could be twins. But they are not identical. The US’s Bristol-Myers Squibb and the UK’s AstraZeneca are both...

  32. May 31, 2012

    AstraZeneca prepares for upheaval

    The new chairman of AstraZeneca says his top priority is finding a permanent chief executive for the troubled Anglo-Swedish...

  33. May 22, 2012

    Global pharma: time to do drugs?

    When times are hard, do drugs. In the stock market, this advice is dogma. Shares of global pharma companies are...

  34. May 15, 2012

    AstraZeneca among suitors eyeing Amylin

    Amylin Pharmaceuticals, the US maker of diabetes-focused medicines, has attracted a string of potential suitors, including...

  35. May 6, 2012

    Drugmakers see $33bn bout of M&A activity

    A recent spate of takeovers in healthcare, as drugmakers seek to replace expiring drug patents, has made it the busiest...

  36. May 6, 2012

    Pharma tries to avoid falling off ‘patent cliff’

    For four years Chris Viehbacher has been bracing himself for a nasty turn. Since being appointed Sanofi’s chief executive in...

  37. April 26, 2012

    Bristol-Myers reveals it is subject of probe

    Bristol-Myers Squibb, the US drug company, revealed in a filing on Thursday that the US Securities and Exchange Commission...

  38. April 23, 2012

    Nestlé/Pfizer: earnings in infancy

    There’s one born every minute – or that, at least, is what Nestlé’s latest acquisition implies. The Swiss food group is...

Search for Bristol-Myers Squibb Co and